NTRA Stock Forecast: Natera, Inc. Price Predictions for 2026-2027
The 23 Wall Street analysts covering Natera, Inc. hold a median 12-month price target of $408 — +49.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Natera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NTRA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NTRA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +49.3% from it.
Of the 20 most recent actions, 16 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Baird | Maintains | Outperform | $458 → $403 |
| 6 Nov 2026 | Evercore ISI Group | Maintains | Outperform | $468 → $400 |
| 6 Nov 2026 | JP Morgan | Maintains | Overweight | $460 → $405 |
| 27 Oct 2026 | BTIG | Maintains | Buy | $320 → $430 |
| 19 Oct 2026 | Canaccord Genuity | Maintains | Buy | $375 → $500 |
| 14 Oct 2026 | JP Morgan | Maintains | Overweight | $360 → $460 |
| 13 Oct 2026 | Morgan Stanley | Maintains | Overweight | $355 → $435 |
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $340 → $480 |
| 7 Oct 2026 | Barclays | Maintains | Overweight | $340 → $475 |
| 6 Oct 2026 | Citigroup | Maintains | Buy | $365 → $480 |
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $360 → $475 |
| 25 Sept 2026 | RBC Capital | Maintains | Outperform | $350 → $460 |
| 9 Sept 2026 | UBS | Maintains | Buy | $290 → $435 |
| 8 Sept 2026 | Rothschild & Co | Initiates | Buy | $385 |
| 13 Aug 2026 | Citigroup | Maintains | Buy | $315 → $365 |
| 12 Aug 2026 | Guggenheim | Maintains | Buy | $290 → $360 |
| 12 Aug 2026 | Piper Sandler | Maintains | Overweight | $249 → $364 |
| 12 Aug 2026 | Stephens & Co. | Maintains | Overweight | $305 → $350 |
| 7 Aug 2026 | BTIG | Maintains | Buy | $290 → $320 |
| 7 Aug 2026 | Citigroup | Maintains | Buy | $300 → $315 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NTRA.
This page is one stock. Monday covers all of them.
NTRA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NTRA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Natera, Inc. returned +21.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NTRA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 13.6×
- Price / book
- 21.1×
- EV / EBITDA
- —
Cheaper than 10% of US stocks
Cheaper than 3% of US stocks
- Revenue growth (YoY)
- 34.1%
- Earnings growth (YoY)
- —
- Gross margin
- 64.5%
- Operating margin
- −8.5%
- Net margin
- −5.7%
Higher than 80% of US stocks
Higher than 78% of US stocks
Higher than 27% of US stocks
Higher than 24% of US stocks
- Return on equity
- −10.6%
- Return on assets
- −6.8%
- Dividend yield
- —
Higher than 36% of US stocks
Higher than 30% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Natera, Inc. has a market value of $39.6B and an enterprise value of $38.8B.
Revenue in the twelve months to 30 June 2026: $2.7B. The latest quarter grew 37.7% year on year.
Net income over the same four quarters: −$192.3M, a −7.1% net margin.
Free cash flow in the twelve months to 30 June 2026: $51.2M.
Natera, Inc. employs 4,424 people — $612K of revenue per employee.
Data provided by Twelve Data
NTRA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NTRA’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Natera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NTRA
What is the NTRA stock price forecast for 2026-2027?
The 23 Wall Street analysts covering Natera, Inc. have a median 12-month price target of $408, with estimates ranging from $280 to $500. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NTRA stock a buy right now?
Of the 23 analysts covering Natera, Inc., 21 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Natera, Inc. 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NTRA?
As at 21 Nov 2026, Natera, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
Will NTRA stock go up?
No one can know that. What the data says: the median 12-month target from 23 analysts implies +49.3% from the last close, and Ticker Nerd's factor model ranks Natera, Inc. 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NTRA stock forecast for 2030?
No analyst covering Natera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $280 to $500 over the next 12 months.
How has NTRA stock performed over the past year?
Natera, Inc. returned +21.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Natera, Inc. do?
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples.
About Natera, Inc.
Natera, Inc. is a molecular diagnostics company that develops and commercializes cell-free DNA and genetic testing services for clinical use. The company focuses on oncology, women’s health, and organ health, using proprietary molecular assays and bioinformatics to help detect and monitor genetic conditions and disease-related changes from small blood samples. Its current product portfolio includes prenatal screening, carrier screening, cancer monitoring, and transplant rejection assessment tests, serving physicians, hospitals, health systems, transplant centers, and biopharma partners. Natera’s tests are used to support areas such as reproductive health, cancer residual disease monitoring, recurrence surveillance, and organ transplant management. Headquartered in Austin, Texas, Natera plays an important role in the growing precision medicine market by providing non-invasive diagnostic tools that help inform clinical decision-making across multiple medical specialties.
CEO Mr. Steven Leonard Chapman · 4,424 employees · United States · https://www.natera.com